UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000027179 |
|---|---|
| Receipt number | R000031102 |
| Scientific Title | A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy. |
| Date of disclosure of the study information | 2017/05/01 |
| Last modified on | 2022/11/01 11:41:50 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
Acronym
A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
Scientific Title
A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
Scientific Title:Acronym
A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
Region
| Japan |
Condition
Condition
pancreatic cancer
Classification by specialty
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the safety and efficacy of TLP0-001 in combination with S-1.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Phase III
Assessment
Primary outcomes
Overall survival
Key secondary outcomes
Progression free survival
Response rate
Adverse events
Rate of dose limiting toxicity (first six patients in active group)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Active group:
TLP0-001 1mL will be administered bi-weekly as 1 treatment course for every 6 weeks. Besides, S-1 80mg/m2 will be administered for 4 weeks followed by a 2-week rest. Administration will be continued until patient's condition meets withdrawal criteria.
Interventions/Control_2
Placebo group:
Placebo 1mL will be administered bi-weekly as 1 treatment course for every 6 weeks. Besides, S-1 80mg/m2 will be administered for 4 weeks followed by a 2-week rest. Administration will be continued until patient's condition meets withdrawal criteria.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 79 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Invasive pancreatic ductal carcinoma histologically or cytologically confirmed as adenocarcinoma or squamous cell carcinoma. Presence of measurable disease is not considered.
(2) Refractory to standard therapy.
-Patient must have treated by Gemcitabine and nab-paclitaxcel at least one time.
-It doesn't matter weather patient had treated by another antitumor drug except for pyrimidine fluoride drug or radiation therapy.
(3) Patients must be >=20 years old and <=79 years old at the time of primary consent.
(4) Karnofsky Performance Status must be >=80.
(5) Patients must have prescribed type of Human Leukocyte Antigen both class I and class II.
(6) Life Expectancy must be >=3 months.
(7) The following criteria must be satisfied in laboratory tests conducted before enrollment. And G-CSF, Erythropoetin, Blood products and transfusion must be untried within 7 days before laboratory tests.
-White blood cell count >=3,000/mm3 ,<=12,000/mm3
-Neutrophil count >=1,500/mm3
-Hemoglobin >= 9.0 g/dL
-Platelet count >=10,000mm3
-Total bilirubin <=2.0 mg/dL(to be permitted <=3.0 mg/dL in patients treated by biliary drainage for obstructive jaundice)
-AST <=150 IU/L
-ALT <=150 IU/L
-Serum Creatinine <=1.5 mg/dL
-Creatinine clearance >=50 mL/min
(8) Oral intake is possible.
(9) The period from the end of previous treatment to the beginning of this trial must be satisfied following criteria.
-antitumor drug : >=15days
-domestic unrecognized drug which has anti-tumor effect. : >=29days, antibody drug : >=57days
-radiotherapy : >=29days
- laparotomy: >=15days
- systemic treatment of corticosteroid: >=15days
(10) Patient must have signed the consent form
Key exclusion criteria
(1) Prior treatment of pyrimidine fluoride drug.
(2) Prior treatment of Cancer immunotherapy.
(3) Active double cancer (include asynchronous double cancer with disease-free duration <=1 year) except carcinoma in situ or intramucosal cancer.
(4) Interstitial pneumonia or pulmonary fibrosis.
(5) History of severe hypersensitivity to S-1 or its component.
(6) History of hypersensitivity to OK-432, penicillin G, Gentamicin or streptomycin.
(7) History of hypersensitivity to pig-derived or mouse derived component.
(8) History of severe allergies (asthmaticus, anaphylactic shock etc).
(9) Water diarrhea.
(10) Cerebral metastasis or being suspected.
(11) Pleural effusion, ascites fluid, or pericardial fluid in need of drainage.
(12) Serious infections or being suspected.
(13) Positive for serum anti-HBs Ag or HBV-DNA.
(14) Positive for HCV Ab, HTLV1 Ab, HIV Ab, syphilis spirochete or parvovirus.
(15) Severe nervous disorder or mental disorder.
(16) Uncontrolled heart disease, pulmonary disease, kidney disease, or liver disease.
(17) Complication of CTCAE Grade 4 or another uncontrolled complication.
(18) Need continuous medication of flucytosine, phenytoin or warfarin.
(19) Patients who require systemic administration of the following agents during the study treatment period.
1.Corticosteroid
2.Immunosuppresant, Immunostimulant
3.Erythropoietin
(20) Autoimmune disease that needs treatment.
(21) Test products can not be prepared to carry out at least one course (three times) from the autologous blood obtained by the apheresis performed before the secondary consent.
(22) Current participation in other clinical trials.
(23) Pregnant females or nursing mothers who can not stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period.
(24) The subject who was determined by investigator that being not adequate to participate in the trial.
Target sample size
185
Research contact person
Name of lead principal investigator
| 1st name | Hiroki |
| Middle name | |
| Last name | Yamaue |
Organization
Wakayama Medical University
Division name
Second Department of Surgery
Zip code
641-8510
Address
811-1 Kimiidera, Wakayama, Japan
TEL
073-441-0613
trial2nd@wakayama-med.ac.jp
Public contact
Name of contact person
| 1st name | Masahiro |
| Middle name | |
| Last name | Katsuda |
Organization
Wakayama Medical University
Division name
Second Department of Surgery
Zip code
641-8510
Address
811-1 Kimiidera, Wakayama, Japan
TEL
073-441-0613
Homepage URL
https://www.wakayama-med.ac.jp/med/chikenkanri/patient/file/28018_nige_sui_170929.pdf
katsuda@wakayama-med.ac.jp
Sponsor or person
Institute
Wakayama Medical University
Institute
Department
Personal name
Funding Source
Organization
Tella pharma, Inc.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Wakayama Medical University Ethics Review Committee
Address
811-1 Kimiidera, Wakayama, Japan
Tel
073-441-0547
chiken@wakayama-med.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
手稲渓仁会病院（北海道）、千葉県がんセンター（千葉県）、千葉徳洲会病院（千葉県）、横浜市立大学病院（神奈川県）、神奈川県立がんセンター（神奈川県）、愛知県がんセンター（愛知県）、名古屋大学病院（愛知県）、富山大学病院（富山県）、大阪市立大学病院（大阪府）、奈良県立医科大学病院（奈良県）、和歌山県立医科大学病院（和歌山県）、山口大学病院（山口県）、九州がんセンター（福岡県）、長崎大学病院（長崎県）、弘前大学病院（青森）、関西医科大学病院（大阪）
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2017 | Year | 03 | Month | 01 | Day |
Date of IRB
| 2016 | Year | 12 | Month | 27 | Day |
Anticipated trial start date
| 2017 | Year | 03 | Month | 14 | Day |
Last follow-up date
| 2024 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2024 | Year | 06 | Month | 30 | Day |
Date trial data considered complete
| 2024 | Year | 09 | Month | 30 | Day |
Date analysis concluded
| 2025 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2017 | Year | 04 | Month | 28 | Day |
Last modified on
| 2022 | Year | 11 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031102
